IGI Logo

Zydus Lifesciences is currently trading at Rs. 929.45, up by 2.95 points or 0.32% from its previous closing of Rs. 926.50 on the BSE.

The scrip opened at Rs. 934.05 and has touched a high and low of Rs. 941.80 and Rs. 927.00 respectively. So far 35820 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 797.05 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 941.80 and Rs. 916.85 respectively. The current market cap of the company is Rs. 94163.38 crore.

The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.33% and 6.68% respectively.

Zydus Lifesciences’ wholly owned subsidiary -- Zynext Ventures USA LLC (Zynext) has entered into Securities Purchase Agreement (SPA) with Agenus Inc., USA to acquire 2,133,333 shares of common stock having par value of $0.01 per share, representing 5.9% of the paid-up share capital of the Agenus Inc. (on fully diluted basis) at a purchase price of $7.50 per share aggregating to around $16 million.

Agenus’ lead programme comprising Botensilimab (BOT) and Balstilimab (BAL), is a nextgeneration immunotherapy platform designed to strengthen and sustain the immune system’s response against tumour cells. Currently in advanced clinical trials, BOT/BAL have demonstrated significant clinical activity across nine cancer types in more than 1,200 patients, including both late-stage and neoadjuvant settings. 

The proposed investment in the shares of the Agenus Inc. aligns with the company’s objective of advancing life-changing therapies and offering novel solutions anchored on science, innovation and health to empower patients. Its extensive global partner network will help propel the Agenus Inc’s programmes and unlock their full potential. 

In addition to capital, Zynext Ventures will bring deep expertise in data analytics and access to a broad global network of biotech, regulatory, and clinical partners. This synergistic approach aims to unlock new avenues for Agenus, enabling the company to broaden the application of its BOT/BAL programme into earlier lines of treatment and address a wider spectrum of cancers with significant unmet medical needs. The acquisition is expected to be completed within 60 days from the date of execution of the definitive agreement, with a potential 30- days extension.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.